PumasAI has helped establish a new computational laboratory in India focused on artificial intelligence, pharmacometrics and model-informed drug development.
The Dr Ramalingam Sankaran Computational Lab for Quantitative Sciences has been launched at PSG Institute of Medical Sciences and Research, known as PSGIMSR, in Coimbatore, India.
The facility has been developed through a collaboration between PumasAI, the Society of Pharmacometrics and Health Analytics Sciences and PSGIMSR. It is intended to support education, research and computational infrastructure for clinical pharmacology, healthcare data analytics and quantitative sciences.
Computational infrastructure for drug development
The laboratory is powered by a high-performance computing cluster, giving students, researchers and healthcare professionals access to advanced computational resources.
According to PumasAI, the facility will support work in AI-driven drug discovery, predictive health modelling, real-world evidence generation and model-informed drug development.
Model-informed drug development, often referred to as MIDD, uses mathematical and statistical modelling to support decisions across the drug development lifecycle, including dose selection, trial design and regulatory strategy.
“Scientific innovation begins with people,” said Dr Vijay Ivaturi, Co-Founder and CEO of PumasAI.
He said access to advanced computational resources and modern AI technologies could create opportunities beyond a single institution.
“This laboratory represents an investment in future scientists, future discoveries, and ultimately better outcomes for patients around the world,” Ivaturi said.
Training the next generation of pharmacometrics researchers
The facility will support research across clinical pharmacology, pharmacometrics, machine learning and healthcare analytics.
Students and researchers are expected to take part in live research projects, industry collaborations and translational research initiatives. The aim is to give participants practical experience applying AI to drug development, clinical data modelling, pharmacometric simulations and population health analytics.
The lab also strengthens the educational foundation of SOPHAS’ AI in Drug Development programme by providing dedicated computational infrastructure for advanced scientific research.
The facility is named in honour of Dr Ramalingam Sankaran, former Dean of PSGIMSR and founding President of SOPHAS, recognising his contribution to quantitative science and computational research in India.
India’s role in AI-enabled pharmaceutical research
India continues to expand its role in global pharmaceutical innovation through investment in research capacity, technology and life sciences talent.
The new lab adds to this momentum by giving researchers access to computational tools and training for quantitative drug development, a field that increasingly combines clinical pharmacology, statistics, simulation and machine learning.
The US Food and Drug Administration describes pharmacometrics as a science that quantifies drug, disease and trial information to support efficient drug development and regulatory decisions. AI and machine learning are increasingly being explored within this broader quantitative framework.
“Our vision extends beyond building software,” Ivaturi said. “We want to help build the scientific ecosystem that powers the next generation of innovation.”
He said the success of the initiative would be measured by the discoveries it supports, the researchers it develops and the therapies that ultimately improve lives.
The Dr Ramalingam Sankaran Computational Lab for Quantitative Sciences was officially inaugurated on 13 July 2026 by Sri L Gopalakrishnan, Managing Trustee of PSG & Sons’ Charities Trust, alongside leaders from PSGIMSR, SOPHAS and PumasAI.
More information about PumasAI is available at pumas.ai.
FAQs
What has PumasAI helped launch?
PumasAI has helped establish the Dr Ramalingam Sankaran Computational Lab for Quantitative Sciences at PSGIMSR in Coimbatore, India.
What will the computational lab focus on?
The lab will support research and training in artificial intelligence, clinical pharmacology, pharmacometrics, healthcare data analytics and model-informed drug development.
Who developed the lab?
The lab was developed through a collaboration between PumasAI, the Society of Pharmacometrics and Health Analytics Sciences and PSG Institute of Medical Sciences and Research.
What is model-informed drug development?
Model-informed drug development uses mathematical, statistical and computational models to support decisions in drug development, including dose selection, clinical trial design and regulatory strategy.
When was the lab inaugurated?
The Dr Ramalingam Sankaran Computational Lab for Quantitative Sciences was officially inaugurated on 13 July 2026.
